Overall, this evidence suggests that individuals with cancer and a higher circulating CRP level have an increased risk of developing a first thrombosis, and a higher risk of recurrence following treatment for CAT if the CRP level remains high after cessation of anticoagulation. This evidence concerns the gene CRP and cancer.